Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Merck of Germany Considers Entry into Japanese Biosimilars Market
June 18, 2012
- Pharmacists Predict Further Use of Mucosta Generics: Survey
June 18, 2012
- Asklep to Establish Subsidiary in Taiwan, Buffing Up CRO Business in Asia
June 15, 2012
- Antiallergic Agent S-555739 Shows Efficacy in Combination Therapy in PIIb Study: Shionogi
June 15, 2012
- Sales of Januvia, Cervarix Exceed 50 Billion Yen in 2 Years since Launch
June 15, 2012
- DPP-4 Inhibitors Surged, RA Treatments Maintained Strong Growth in FY2011
June 15, 2012
- Top 100 Products in FY2011: Pronounced Growth for ARB Combinations with Declining Sales of Monodrugs
June 15, 2012
- Sanofi, Hisamitsu to Form JV for Allergy-Related OTCs, Seen Eyeing Allegra OTC Launch
June 14, 2012
- Janssen Pharmaceutical to Enlarge Plant Expecting 2.7 Times Current Shipping Volume
June 14, 2012
- Astellas to Collaborate with DNDi on Drug Discovery for Tropical Diseases
June 14, 2012
- MTPC to Launch Tenelia in Sept., Expecting to Become a Growth Driver: President Tsuchiya
June 14, 2012
- Midazolam is Most Used Sedative in Terminal Care: Doctor Survey
June 13, 2012
- Japan Vaccine to Develop, Supply All Vaccines Needed in Japan by 2020
June 13, 2012
- Astellas Launches Dificlir in Europe
June 13, 2012
- Sanofi-Aventis Files NDA for GLP-1 Receptor Agonist Lixisenatide in Japan
June 13, 2012
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…